<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607980</url>
  </required_header>
  <id_info>
    <org_study_id>20190232</org_study_id>
    <secondary_id>2020-003184-25</secondary_id>
    <nct_id>NCT04607980</nct_id>
  </id_info>
  <brief_title>A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654&#xD;
      compared with ustekinumab in participants with moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter study and will enroll approximately 542 participants.&#xD;
&#xD;
      The total duration of study participation for each participant will be 56 weeks, with up to 4&#xD;
      weeks for screening, and for 52 weeks after the first administration of either ABP 654 or&#xD;
      ustekinumab.&#xD;
&#xD;
      After confirmation of eligibility, all participants will be randomized in a 1:1 ratio into 2&#xD;
      treatment groups (Group A will receive ABP 654, and Group B will receive ustekinumab)&#xD;
      stratified by prior biologic use for psoriasis (yes versus [vs] no), geographic region, and&#xD;
      baseline body weight (BW).&#xD;
&#xD;
      Based on the psoriasis area and severity index (PASI) score (to determine better improvement&#xD;
      or partial improvement) at week 28, the participants in the study will proceed as follows:&#xD;
&#xD;
        1. Participants who do not achieve PASI 50 response or better improvement at Week 28 will&#xD;
           be considered to have completed the study and will complete end of study procedures (ie,&#xD;
           week 52 procedures), and those unable to complete week 28 visit, or did not have a PASI&#xD;
           assessment completed, will be discontinued from the study.&#xD;
&#xD;
        2. Participants who achieve PASI 75 response or better improvement will continue on the&#xD;
           study and will be re-randomized in a blinded fashion such that participants initially&#xD;
           randomized to Group A (ABP 654) will continue to receive ABP 654 and those in Group B&#xD;
           (ustekinumab) will re-randomized, to either continue on ustekinumab (Treatment Group B1)&#xD;
           or switch to ABP 654 (Treatment Group B2).&#xD;
&#xD;
        3. Participants with PASI 50 response or better but less than PASI 75 response and on the&#xD;
           Investigator's decision, participants will continue on the originally assigned treatment&#xD;
           with dose intensification and will not be re-randomized. However, participants that do&#xD;
           not dose intensify will be re-randomized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">June 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Investigators, study personnel with the exception of the clinical research organization's unblinded biostatistician and unblinded programmers; and the data monitoring committee, and the study participants will remain blinded to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Improvement in PASI From Baseline to Week 12</measure>
    <time_frame>Baseline (Day 1 [Week 0]) until Week 12</time_frame>
    <description>The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Improvement in PASI at Other Timepoints</measure>
    <time_frame>Baseline (Day 1 [Week 0]), weeks 4, 12, 16, 28, 36, 40, 44 and Week 52 (end of study [EOS])</time_frame>
    <description>The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with PASI 75 Response Throughout the Study</measure>
    <time_frame>Baseline (Day 1 [Week 0]), weeks 4, 12, 16, 28, 36, 40, 44 and Week 52 (EOS)</time_frame>
    <description>Reduction in disease as measured by PASI score. The PASI 75 response is a 75% or greater improvement (reduction in disease [PASI 75]) from baseline in PASI score. The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with PASI 100 Response Throughout the Study</measure>
    <time_frame>Baseline (Day 1 [Week 0]), weeks 4, 12, 16, 28, 36, 40, 44 and Week 52 (EOS)</time_frame>
    <description>Reduction in disease as measured by PASI score. The PASI 100 response is a 100% improvement (reduction in disease [PASI 100]) from baseline in PASI score. The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling; each graded on a 0-4 scale (0 = clear; 1-4= increasing severity) of the lesions, weighted by the area of involvement in the four main body areas (i.e., head, arms, trunk to groin, and legs to top of buttocks). The PASI score ranges from 0 to 72. The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Static Physician's Global Assessment (sPGA) Responses (0/1) at Week 12 and Week 52</measure>
    <time_frame>Week 12 and Week 52</time_frame>
    <description>The sPGA is a 6-point scale ranging from 0 (clear) to 5 (very severe) used to measure the severity of disease (induration, scaling, and erythema). A sPGA response is defined as a sPGA value of clear (score 0) or almost clear (score 1). The higher score represents the worse symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Body Surface Area (BSA) Affected with Psoriasis at Week 12 and Week 52</measure>
    <time_frame>Week 12 and Week 52</time_frame>
    <description>The percent of BSA affected (%BSA) is estimated by assuming that the participant's palm, excluding the fingers and thumb, represents roughly 1% of the body's surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants With Treatment Emergent Adverse Events and Serious Adverse Events</measure>
    <time_frame>From Screening Day until Week 52 (EOS)</time_frame>
    <description>Assessment of the safety of ABP 654 compared with ustekinumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of Interests (EOIs)</measure>
    <time_frame>From Screening Day until Week 52 (EOS)</time_frame>
    <description>Assessment of the safety of ABP 654 compared with ustekinumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-drug Antibodies (ADAs) to ABP 654</measure>
    <time_frame>Pre-dose on weeks 0 (day 1), 4, 12, 28, 32, 40, and on Week 52 (EOS)</time_frame>
    <description>The detection and characterization of antibodies to ABP 654 will be performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">563</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment Group A (ABP 654)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) injection of ABP 654, 45 mg (baseline BW less than equal to [&lt;=] 100 kg) or 90 mg (baseline BW greater than [&gt;] 100 kg) at weeks 0, 4, and 16. Further from week 28 participants will receive ABP 654 (same dose) every 12 weeks (Q12W) at weeks 28 and 40 or may receive dose intensification Q8W at weeks 28, 36, and 44, depending on PASI score.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B (Ustekinumab - ABP 654)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC injection of ustekinumab,45 mg (baseline BW &lt;= 100 kg) or 90 mg (baseline BW &gt; 100 kg) at weeks 0, 4, and 16. At week 28, participants will be re-randomized to continue on ustekinumab (Treatment group B1), or to receive ABP 654 (Treatment group B2) on weeks 28 and 40. Depending on PASI score, some participants may not be re-randomized and may receive dose intensification with ustekinumab Q8W at weeks 28, 36, and 44.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP 654</intervention_name>
    <description>Participants will receive SC injection of ABP 654.</description>
    <arm_group_label>Treatment Group A (ABP 654)</arm_group_label>
    <arm_group_label>Treatment Group B (Ustekinumab - ABP 654)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Participants will receive SC injection of ustekinumab.</description>
    <arm_group_label>Treatment Group B (Ustekinumab - ABP 654)</arm_group_label>
    <other_name>Stelara®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          -  Stable moderate to severe plaque psoriasis for at least 6 months&#xD;
&#xD;
          -  Baseline score of PASI &gt;= 12, involvement of &gt;= 10% BSA, and sPGA &gt;= 3 at screening&#xD;
             and at baseline&#xD;
&#xD;
          -  Candidate for phototherapy or systemic therapy&#xD;
&#xD;
          -  Previous failure, inadequate response, intolerance, or contraindication to at least 1&#xD;
             conventional anti-psoriatic systemic therapy&#xD;
&#xD;
          -  Female participants should have negative serum pregnancy test during screening and a&#xD;
             negative urine pregnancy test at baseline&#xD;
&#xD;
          -  No known history of latent or active tuberculosis (TB), and has a negative test for TB&#xD;
             during screening (with negative purified protein derivative (PPD), and Negative&#xD;
             Quantiferon®/T-spot test)&#xD;
&#xD;
          -  Participants with a positive purified protein derivative and a history of Bacillus&#xD;
             Calmette-Guérin (BCG) vaccination are allowed with a negative Quantiferon®/T-spot®&#xD;
&#xD;
          -  Participants with a positive PPD test (without history of BCG vaccination) or&#xD;
             participants with a positive or indeterminate Quantiferon®/T-spot test are allowed if&#xD;
             they have all of the following:&#xD;
&#xD;
               -  No symptoms per TB worksheet provided by the sponsor&#xD;
&#xD;
               -  Documented history of adequate prophylaxis initiation prior to receiving&#xD;
                  investigational product (IP) in accordance with local recommendations&#xD;
&#xD;
               -  No known exposure to a case of active TB after most recent prophylaxis&#xD;
&#xD;
               -  No evidence of active TB on chest radiograph within 3 months prior to the first&#xD;
                  dose of IP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Skin disease related conditions such as, Erythrodermic psoriasis (PsO), pustular PsO,&#xD;
             guttate PsO, medication induced PsO, or other skin conditions at the time of the&#xD;
             screening visit (eg, eczema) that would interfere with evaluations of the effect of IP&#xD;
             on PsO&#xD;
&#xD;
          -  Participant has an active infection, recurrent or chronic infections, serious&#xD;
             infection or history of infections&#xD;
&#xD;
          -  Known history of human immunodeficiency virus&#xD;
&#xD;
          -  Hepatitis B surface antigen or hepatitis C virus antibody positivity at screening&#xD;
&#xD;
          -  Uncontrolled, clinically significant systemic disease such as uncontrolled diabetes&#xD;
             mellitus, cardiovascular disease, renal disease, liver disease, or hypertension&#xD;
&#xD;
          -  Moderate to severe heart failure (New York Heart Associate class III/IV)&#xD;
&#xD;
          -  Known hypersensitivity to the IP or to any of the excipients&#xD;
&#xD;
          -  Any abnormal laboratory parameters at screening, as defined in protocol&#xD;
&#xD;
          -  Previous treatment with any agent specifically targeting interleukin (IL)-12 or IL-23&#xD;
&#xD;
          -  Received biologic treatment for psoriasis within the previous month or 5 drug&#xD;
             half-lives prior to randomization&#xD;
&#xD;
          -  Received non-biologic systemic psoriasis therapy within 4 weeks prior to randomization&#xD;
&#xD;
          -  Received Ultra-violet A (UVA) phototherapy (with or without psoralen) or excimer laser&#xD;
             within 4 weeks prior to randomization, or ultra-violet B (UVB) phototherapy within 2&#xD;
             weeks prior to randomization&#xD;
&#xD;
          -  Received topical psoriasis treatment within 2 weeks prior to randomization (exception:&#xD;
             upper mid-strength to least potent [class III to VII] topical steroids permitted on&#xD;
             the palms, soles, face, and intertriginous areas; bland emollients)&#xD;
&#xD;
          -  Received live viral or live bacterial vaccination within 2 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Received BCG vaccination within 1 year prior to randomization&#xD;
&#xD;
          -  Other investigational procedures within 4 weeks prior to randomization and during the&#xD;
             study&#xD;
&#xD;
          -  Participants not agreeing to follow protocol defined contraceptives procedures&#xD;
&#xD;
          -  Participants likely not to be available to complete all protocol-required study visits&#xD;
             or procedures, and/or to comply with all required study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Dermatology and Mohs Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luis Dermatology and Laser Clinic - Dermatology</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unison Clinical Trials</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revival Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609-2230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703-2403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250-2041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epiphany Dermatology of Kansas, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALLCUTIS Research, Inc.</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Boston Clinical Partners</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, LLC.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services, PLLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bexley Dermatology Research</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209-2421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologists of Southwest Ohio</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040-4520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pennsylvania Centre for Dermatology, LLC</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studies in Dermatology, LLC</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research - Dermatology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research [Texas]</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acclaim Dermatology</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beacon Dermatology</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCA Medical Research</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsway Clinical Research</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8X 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research Inc</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre Inc.</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JRB Research Inc.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Research Centre - Dermatology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 Medical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche dermatolog</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vahlberg &amp; Pild OÜ</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10134</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Confido Private Medical Clinic - General Practice/Medicine</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis Dres.Scholz Sebastian Schilling</name>
      <address>
        <city>Mahlow</city>
        <state>Brandenburg</state>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Zentrum Osnabrueck Nord</name>
      <address>
        <city>Bramsche</city>
        <state>Niedersachsen</state>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum im Jahrhunderthaus</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentroDerm GmbH</name>
      <address>
        <city>Wuppertal</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brgyógyászati és Allergológiai Magánrendelés</name>
      <address>
        <city>Szolnok</city>
        <state>Jász-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNOMEDICALTRIALS Kft</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Centre 4 Ltd., Diagnostics Centre</name>
      <address>
        <city>Riga</city>
        <state>Rga</state>
        <zip>LV-1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga 1st hospital, Clinic of Dermatology and STD</name>
      <address>
        <city>Riga</city>
        <state>Rga</state>
        <zip>LV1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.Kisis LtD</name>
      <address>
        <city>Riga</city>
        <state>Rga</state>
        <zip>LV1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health and Aesthetics Ltd</name>
      <address>
        <city>Riga</city>
        <zip>LV-1009</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smite Aija doctor practice in dermatology, venereology</name>
      <address>
        <city>Talsi</city>
        <zip>LV3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lietuvos sveikatos mokslu universiteto ligonine Kauno klinik</name>
      <address>
        <city>Kaunas</city>
        <state>Kauno Apskritis</state>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilniaus universiteto ligonine Santaros klinikos Dermatovenerologijos centras</name>
      <address>
        <city>Vilnius</city>
        <state>Vilniaus Apskritis</state>
        <zip>LT-08411</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermMedica Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnolskie</state>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <state>Lskie</state>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia i Urody Maxxmed</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne ALL-MED</name>
      <address>
        <city>Krakow</city>
        <state>Maopolskie</state>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Warszawa</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-793</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambroziak Dermatologia</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-953</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royalderm Agnieszka Nawrocka</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Naukowo-Leczniczy Iwolang sp. z.o.o.</name>
      <address>
        <city>Iwonicz Zdroj</city>
        <state>Podkarpackie</state>
        <zip>38-440</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specderm Poznanska Sp. j.</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp. J.</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solumed</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Rewerska Diamond Clinic</name>
      <address>
        <city>Krakow</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-412</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WroMedica I. Bielicka, A. Strzalkowska s.c.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Skierniewice</name>
      <address>
        <city>Skierniewice</city>
        <state>Ódzkie</state>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>Psoriasis area and severity index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

